advance if you well call. losing Thank all me voice, you us in that everybody. this I'm can't apologize; through for my I so want Welcome, to apologies hear joining Anna. the Thanks, afternoon.
for has a Rubraca Let's ago. in Rubraca. was begin with field We a share selling are our achieved there year for you the indication granted one Rubraca commercial year. cancer fairly that XXXX quarter in narrow million ovarian remind initial over I'll during XX, and for December net a review of the mutation specific treatment our just $XX for out been million the team and $XX.X full fourth sales approval
value news free $X.X assistance full the through As in release, the the include and in fourth year noted in not provided million commercial quarter for eligible does our to patients the $XX.X program. million patients of supply this drug
over third prescribed in have Rubraca. to despite As it the quarter, Sales providers two increased growth, inhibitors of Since fourth the very and represent overall last over quarter other nearly and therapy approximately quarter slightly XXX commercial for approvals we've fourth healthcare consecutive the X,XXX were this had four in patients broader continues supply. initiated have levels. did of XX% the substantially PARP quarters
requirement was PARP BRCA. the mutations for quarters approved now XXXX, In describe setting diagnostic maintenance second a fact, treatment ovarian inhibitors and second our Rubraca line of the cancer line the treatment all-comers for of time second launch, In for in in rapidly U.S. approved became for with participating third I'll inhibitor which first the At no briefly. are testing. evolving in the we the later patients market indicated of PARP with
line population rapidly maintenance PARP result treatment with our own a standard the is aerial treatment for in cancer ovarian setting the which pre-dataset, for data of this limits advanced inhibitor. of patient the becoming care including patients third As available
on of to identify mutant rapidly treating with BRCA converse tissue-based the addressing patients that approved and sort all review of FEA. about a maintenance that Based or are the to once and opportunity of frustrations study, diagnostic by choice provide XX% diagnostic NDA become at testing. avoid in results delays I'll ordering currently has FDA the a all-comers from in and clearly enthusiastic apparent cost this it highly times, physicians the associated taking test advantage addition, of In new given will detail competitive the We're very population the moments. Rubraca the we supplemental on these few ARIELX believe data by more under be just
which from our indication Rubraca PDUFA of of as maintenance this first the prescribed our the strong date and the population to same in relatively the for are and profile clinicians U.S. experience we're Rubraca of clinical their ovarian headwinds launch have patients. are population to the Rubraca maintenance using community. confidence physicians We increases. familiarity cancer resulting now despite mutant today year the Many second-line today with the So reflected of X, full general are in a prescribers performance believe limited be continues of with potentially that potential approval upon small upto label. April it of addressable a with adoption the BRCA course pleased who the of broader Overall, gaining
headwinds tailwinds upon our should become anticipated these approval maintenance setting. course, in Of the
results, maintenance receipt quarter mentioned sales the to approval modestly As to Rubraca. of stable for the we've indication until achieved an we for up and in continue on to third our as be quarter call fourth expect
well receiving the from feedback provides clear the that the to profile clinicians patients. is Rubraca are benefit clinical about we their experience with regarded suggest and of Importantly, Rubraca
platinum access now noted were soon. on The for to earlier, based response fallopian progress with to primary these FDA regulatory ARIELX with providing approval highlight all-comers NDA data with maintenance very look regulatory can followed PDUFA in our comprehensive embraced in ovarian Europe. the hopefully are it's April now and the sometime epithelial Rubraca and as this an data treatment cancer of U.S., ARIELX, our drug. in The so by I'll a the XXXX our maintenance cancer both, the which on Starting We well, will supplemental or X. chemotherapy. presentation include to believe patients to for publication and our recurrent forward the turn September at to ARIELX excitement who June process topline ARIELX U.S. with seek As between data beginning and data Europe to or for a compete patients that The enthusiasm date we these U.S. for and U.S. the by approval results our have label to and subsequent gratified based XXXX. in potential X, is enthusiasm this the to-date based well recurrent submission discussing upon indications, have been on and from of approval second-line population been complete seek tube perennial in dataset is our important to with ESMO update as ovarian result, in very April robust We've Lancet. partial our the drives effort for
Turning now regulatory progress to in our Europe.
Our European submission cancer the XXXX, was mutant fourth quarter and the for ovarian EMA. treatment remains during Rubraca the of BRCA third-line accepted under for setting review by
we a held Rubraca February and that vote CHMP oral As meeting for advisory earlier communicated us following was scientific trend a positive to explanation an week, group meeting at week. their the last announced last
at It's Rubraca important submission for based on formal approval on statement vote, or potential less we broader CHMP particularly required the the platinum-sensitive with on indication all-comers indication disease subset We Pending be to and for receipt is positive a approval review treatment CHMP ARIELX. in a to will the those to need. clock. would intend months the potential focused upon second-line follow opinion note the for receipt familiar the there the maintenance hold CHMP of indication, XXXX of a processes is the opinion the for Commission by in medical submit later approval, to first high late include also authorization maintenance year Upon of We final We March, a at on second treatment anticipate to population XXXX. approval European meeting. a by communicated a assuming be their quarter by European treatment where positive March the anticipate vote marketing the or end here vote unmet intent regulatory the indication on the this indication second called that that variation reviewed to what's directed of the a six XXXX.
Beyond treatment would in the potential benefits lead maintenance of also indication. the treatment a indication itself, rapid a approval we pleased review are more broader to that all-comers the for
commercial of planned Given this in medical countries. reimbursement including the timing, leadership the will obviously coincide European we out actively majority with affairs the hires, sales our building teams; forces approval are European individual and
We supply our chain course, have Cambridge, and clinical regulatory safety, also now in at place teams office. our of UK quality
first-in-class metastatic their Opdivo ovarian as the Bristol-Myers Squibb agreement Bristol-Myers prostate of evaluate development our collaboration for clinical combination In pivotal an and X inhibitor Squibb PARP to turn announced our me clinical July, cancer nivolumab advanced broad late Rubraca let to a combination immunotherapy update clinical Phase as castration-resistant of triple and or studies Rubraca. well collaboration clinical trial with and advanced breast in X Phase trials broad in cancer, negative clinical and BMS, including on or in multiple the cancer. Now Opdivo
in Opdivo working the half breast studies triple by closely and in first completed begin first-line United population in our cancer have initiated of patients will study and and running, similar cancer advanced get in or late treatment initiation. with conducted all cancer study, design X/X is XXXX Europe between Rubraca greatest with equally fallopian about in and sponsored, be conducted leader BMS countries. of pivotal and and Phase in as sponsored, XXXX. is with with platinum-based Clovis. collaboration initiated a conducted the breast to ovarian, funded and the peritoneal an ovarian prostate opportunity the to as trial Squibb by are CRPC all-comers triple-negative enthusiastic in up patients metastatic, advanced and and in the of Rubraca, a arm X XXX at evaluate study combination be of ARIELX. study in Rubraca conducted high-grade vision create statistical These with equally The partner advanced cancers negative BMS is are study stage studies a BMS This later be a and safety includes Rubraca shared and and to maintenance studies benefit metastatic efficacy Phase to plus Opdivo; with expected prostate The States, costs will both and to cancer multiple us Clovis. manner expected be We the describe X,XXX sponsored a with We're ATHENA with conducted plan castration-resistant and patients. Bristol-Myers likely date, to placebo BMS the is in clinical BMS. study being these X X in who pivotal study late shared ovarian all advanced study will patients closer XXXX step-down a immuno-oncology, The sponsored extremely and provides during by Opdivo chemotherapy. focus will Opdivo for our indications, will BMS. how on known primary total The important, It company which should strategic patients. study to timely a with additional developed tube, stage newly-diagnosed of evaluate approximately larger in cancer hopefully funded a
a Turning Rubraca of with versus open ARIELX, study is Phase cancer for survival. ovarian including is progression-free randomized start lines after with ovarian relapsed tumors in mutant now prior cancer this studies program; enrollment. BRCA have It study multi-center progressed confirmatory of is or of rest our those in development which I'll company-sponsored primary of study X presently more Rubraca endpoint the setting two patients to chemotherapy treatment cancer, the the ovarian confirmatory therapy, our
are patients. had two We also that trials prostate actively cancer Clovis sponsored enrolling
overall or radiological, in a The who one with Phase patients TRITONX, patients and ATM of study, submission androgen-receptor X The trial is without response chemotherapy targeted BRCA, in in rate other response after or sponsored designed receiving support If to arm taxane-based mutations one of first primary endpoints have planned line prostate somatic germline disease. or lines accelerated castrate-resistant inclusive of is tumors therapy in NDA mutation patients have repair setting. two or this measurable trial HR Clovis PSA disease single our successful, approval. an and or who genes are a the deleterious measurable progressed supplemental
medical TRITONX meeting are we planning the fall, data hopefully to a study initial present As an as the study, at open-label from in ESMO.
advanced include be drug data Our prostate intent in XX a would on initial population. cancer patients median genetically view XX defined with to to to this timeline of provide activity true sufficient
will a study yet TRITONX, therapy should ATM other BRCA survival chemotherapy an is primary progressed the sponsored or or mutation comparative or but radiologic of this not includes prostate potentially Clovis germline have confirmatory targeted who second study targeted is Rubraca Our to with of path. as The therapy choice setting. that randomized the in patients AR Phase study castration-resistant progression-free on position study AR TRITONX X Plain accelerated it's somatic sort study received compare a warrant study and could chemotherapy. endpoint tumor
selection the newer studies all-comers evaluate X prior therapy open-label patients. to portion Phase our collaboration is Phase collaborator their This sponsored is dose And and now trial patients Eligible and open trials; cancers. cancer status Phase now the is HRD Rubraca ATLAS have full with turning one triple-negative is enrolling Tecentriq in or study additional a recurrent, as now sponsored are or on ovarian and to dose population called two to dose of is study and combination enrollment. based monotherapy and of complete failed novel who Rubraca. enroll is for breast of cohorts metastatic atezo our those Xb immunotherapy therapies. X finally, single-arm by full Phase recommended X patient with in cancer. study The Genentech-Roche Rubraca atezolizumab Genentech in continues study One most of an this a bladder
PK Clovis newest in safety primary last sponsored RUCA-J, is our which with The was week. first the patient called dealt X Japanese Our study study in Rubraca with study Phase is sites Japanese the of recommended potential strategy patients studies. rucaparib global Japanese planned of and endpoint, will which development enable in dose of bridging identify or a in to ongoing inclusion seeks
Now, turn results. to over year call discuss and financial the I'll Dan to fourth quarter full
